background
aim
alreadi
pandem
emerg
data
suggest
increas
associ
heighten
mortal
patient
comorbid
aim
evalu
outcom
hypertens
patient
relat
use
reninangiotensin
system
blocker
rasb
method
systemat
search
medic
databas
march
retriev
publish
articl
english
languag
relat
topic
use
mesh
key
word
result
pool
data
ten
avail
chines
studi
n
report
characterist
comorbid
patient
hypertens
present
nearli
follow
diabet
nearli
establish
cardiovascular
diseas
cvd
approxim
patient
although
emerg
data
hint
increas
mortal
patient
known
hypertens
diabet
cvd
note
adjust
multipl
confound
factor
harm
benefit
patient
receiv
rasb
typic
assess
studi
yet
although
mechanist
plausibl
benefit
harm
possibl
agent
given
express
tissu
receptor
angiotensin
convert
conclus
special
attent
definit
requir
patient
associ
comorbid
includ
hypertens
diabet
establish
cvd
although
role
rasb
mechanist
equipois
patient
stop
drug
point
time
recommend
variou
world
organ
without
advic
health
care
provid
coronaviru
diseas
covid
declar
pandem
word
health
organ
march
soon
satisfi
epidemiolog
criteria
infect
peopl
countri
march
world
wit
half
million
case
death
suggest
magnitud
spread
across
world
sinc
first
report
decemb
wuhan
hubei
provinc
china
emerg
data
suggest
older
patient
comorbid
condit
diabet
hypertens
cardiac
pulmonari
diseas
particular
suscept
compar
gener
popul
higher
mortal
therefor
necessari
relook
subgroup
patient
associ
comorbid
review
articl
collat
avail
evid
emerg
far
outcom
comorbid
patient
focus
outcom
patient
hypertens
analyz
controversi
surround
use
reninangiotensin
system
blocker
rasb
systemat
search
pubm
medic
databas
till
march
use
mesh
key
word
includ
coronaviru
hypertens
diabet
cardiovascular
diseas
angiotensin
receptor
blocker
angiotensin
convert
enzym
inhibitor
retriev
avail
literatur
publish
english
languag
report
outcom
differ
comorbid
associ
hypertens
diabet
patient
unexpect
given
rise
preval
chronic
diseas
global
interestingli
pool
data
ten
chines
studi
n
report
characterist
comorbid
patient
associ
hypertens
diabet
presenc
establish
cardiovascular
diseas
cvd
larger
vari
averag
averag
averag
respect
tabl
establish
cvd
also
present
nearli
italian
studi
patient
consist
associ
hypertens
patient
across
studi
uniqu
concern
need
seriou
attent
increas
mortal
two
chines
studi
work
direct
todat
patient
zhou
et
al
found
hypertens
odd
ratio
ci
p
diabet
ci
p
wherea
presenc
coronari
arteri
diseas
ci
p
inhospit
mortal
univari
analysi
howev
associ
disord
mortal
longer
signific
multivari
regress
analysi
similarli
analysi
patient
wu
et
al
found
hypertens
hazard
ratio
hr
ci
p
acut
respiratori
distress
syndrom
ard
ci
p
death
diabet
patient
hr
ci
p
ard
hr
ci
p
death
bivari
cox
regress
analysi
note
howev
neither
studi
adjust
confound
variabl
nevertheless
studi
patient
guo
et
al
report
nearli
twice
increas
mortal
patient
establish
cvd
rais
troponin
tnt
compar
patient
without
cvd
rais
tnt
vs
respect
chines
center
diseas
control
prevent
summari
report
report
case
fatal
rate
cfr
death
among
confirm
case
howev
cfr
elev
hypertens
diabet
presenc
cvd
unsurprisingli
base
find
research
recent
propos
cours
treatment
prognosi
stratifi
base
absenc
presenc
comorbid
type
b
c
type
denot
patient
pneumonia
without
comorbid
type
b
denot
pneumonia
comorbid
wherea
type
c
denot
patient
multiorgan
dysfunct
nonetheless
still
remain
unclear
whether
increas
associ
hypertens
heighten
risk
mortal
directli
relat
hypertens
associ
comorbid
antihypertens
treatment
grow
concern
associ
hypertens
cvd
may
confound
treatment
certain
antihypertens
medic
rasb
although
recent
paper
propos
stop
rasb
suggest
replac
calcium
channel
blocker
treat
hypertens
patient
hypothesi
question
sever
colleagu
entri
coronaviru
cell
facilit
spike
protein
attach
receptor
host
cell
protein
need
prime
serin
proteas
name
protein
differ
coronavirus
may
utilis
differ
receptor
mer
utilis
sar
cov
sar
utilis
angiotensin
convert
effici
interact
sprotein
may
key
determin
transmiss
viru
viral
replic
sever
diseas
theori
effici
could
influenc
chang
amino
acid
substitut
either
viral
sprotein
major
outbreak
sar
cov
occur
minor
localis
outbreak
mild
symptom
observ
sprotein
sar
cov
outbreak
bound
receptor
much
effici
sar
cov
outbreak
consist
absenc
humantohuman
transmiss
latter
outbreak
sever
molecular
chang
sprotein
influenc
bind
human
exampl
substitut
threonin
serin
posit
protein
reduc
bind
similarli
asparagin
posit
increas
bind
affin
methyl
posit
also
shown
influenc
bind
recent
sprotein
sar
shown
similar
sar
cov
bar
gain
function
mutat
import
glutamin
posit
receptor
bind
domain
explain
increas
transmiss
compar
sar
cov
b
chang
receptor
regard
merscov
employ
receptor
cellular
entri
naturallyoccur
polymorph
impact
cellular
entri
merscov
might
thu
modul
mer
develop
infect
patient
possibl
similar
variat
polymorph
could
affect
viral
entri
diseas
cours
polymorph
gene
identifi
howev
evid
affect
suscept
sever
sar
infect
recent
studi
found
differenti
gene
express
human
lung
tissu
racialgend
differ
higher
gene
express
lung
smoker
compar
nonsmok
could
explain
higher
risk
infect
smoker
role
vascular
bed
opposit
angiotensin
convert
enzym
ace
ace
convert
angiotensin
angiotensin
ii
vasoconstrictor
convert
angiotensin
ii
angiotensin
caus
vasodilat
bind
ma
receptor
vascular
bed
downregul
observ
anim
model
lung
injuri
induc
sar
cov
recombin
improv
pulmonari
blood
flow
oxygen
anim
lung
injuri
indic
may
main
determin
lung
injuri
caus
sar
cov
howev
lack
human
data
except
small
studi
patient
acut
respiratori
distress
syndrom
show
recombin
well
toler
led
increas
angiotensin
consider
interest
regard
role
ra
blocker
infect
benefit
harm
postul
figur
illustr
interact
effect
rasb
fig
rational
evid
harm
evid
express
increas
use
ace
inhibitor
arb
especi
heart
kidney
rais
theoret
concern
increas
express
acei
arb
could
facilit
entri
viru
host
cell
increas
chanc
infect
sever
also
increas
express
elderli
extent
predispos
elderli
infect
known
studi
patient
guo
et
al
report
increas
trend
mortal
receiv
rasb
compar
receiv
mortal
patient
without
rasb
respect
inde
increas
associ
heighten
mortal
observ
consist
across
studi
elderli
hypertens
diabet
known
cvd
howev
exactli
known
whether
causal
relat
use
rasb
subgroup
rasb
due
ill
compar
rest
popul
moreov
solid
evid
back
concern
either
infect
coronavirus
b
rational
evid
benefit
discuss
increas
level
coronaviru
infect
could
reduc
lung
injuri
experiment
studi
mice
kuba
et
al
found
losartan
show
significantli
diminish
lung
injuri
pulmonari
edema
acid
aspirationinduc
acut
lung
injuri
addit
sarscov
spike
protein
compar
placebo
similarli
sever
lung
injuri
pulmonari
edema
prevent
recombin
human
infus
losartan
mice
mice
coronaviru
induc
lung
injuri
show
improv
treat
losartan
moreov
retrospect
analysi
found
reduc
rate
death
endotrach
intub
patient
viral
pneumonia
continu
ace
inhibitor
treatment
arb
report
reduc
mortal
ebola
viru
infect
exact
mechan
appar
benefit
drug
coronaviru
infect
yet
clear
howev
could
sever
explan
increas
express
may
result
viral
entri
cell
limit
avail
serin
proteas
camostat
mesyl
inhibitor
shown
inhibit
cellular
entri
sar
could
potenti
therapeut
option
ii
increas
express
cell
membran
may
also
lead
increas
solubl
blood
may
actual
bind
sar
prevent
interact
membran
bound
receptor
iii
ra
blocker
increas
angiotensin
ii
substrat
interact
angiotensin
ii
could
induc
conform
chang
receptor
bind
domain
limit
abil
bind
sar
iv
receptor
present
much
higher
densiti
lung
tissu
children
young
adult
compar
older
individu
thu
upregul
receptor
use
rasb
time
older
peopl
may
emul
ace
express
young
peopl
also
possibl
receptor
increas
function
like
produc
angiotensin
might
provid
resili
targetmedi
destruct
develop
pulmonari
failur
patient
postul
posit
effect
lung
also
protect
overwhelm
infect
v
indiscrimin
discontinu
rasb
patient
heart
failur
may
also
lead
readmiss
hospit
increas
mortal
collect
relationship
ra
activ
use
rasb
sar
infect
scarc
indirect
evid
ra
activ
high
incid
hypokalaemia
regard
use
rasb
retrospect
analysi
hospitalis
patient
cardiovascular
diseas
wuhan
signific
differ
proport
aceiarb
medic
nonsurvivor
survivor
howev
studi
patient
report
guo
et
al
trend
increas
mortal
patient
receiv
rasb
compar
receiv
increasingli
associ
comorbid
includ
hypertens
diabet
special
care
requir
patient
associ
comorbid
given
heighten
risk
inhospit
death
view
lack
robust
evid
either
benefit
harm
bulk
experiment
evid
favour
benefit
reason
patient
continu
use
ace
inhibitor
arb
recommend
european
societi
cardiolog
hypertens
canada
canadian
cardiovascular
societi
uk
renal
associ
intern
societi
hypertens
european
societi
hypertens
american
heart
associ
futur
studi
report
outcom
stratifi
basi
differ
antihypertens
agent
may
enlighten
us
regard
herebi
declar
conflict
interest
relat
articl
